Imaging Method Can Assess Solid Tumor Aggressiveness

This article originally appeared here.
Share this content:
Imaging Method Can Assess Solid Tumor Aggressiveness
Imaging Method Can Assess Solid Tumor Aggressiveness

(HealthDay News) -- The interstitial fluid pressure (IFP) of solid tumors, as measured using a new noninvasive, contrast-enhanced magnetic resonance imaging (MRI) method, may be useful as a novel potential biomarker for tumor aggressiveness and lymph node metastasis, according to a study published in the Oct. 1 issue of Cancer Research.

Noting that elevated IFP may cause metastatic dissemination and resistance to treatment, Tord Hompland, of the Oslo University Hospital in Norway, and colleagues used mouse xenograft models of several types of human cancer to validate the use of gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA) as a contrast agent for dynamic contrast-enhanced MRI (DCE-MRI) for measuring the IFP of solid tumors.

The researchers found that, in all tumor xenografts, there were significant positive correlations between the fluid flow velocity at the tumor surface (v0) and IFP. Higher IFP and v0 were seen in the primary tumors of metastasis-positive mice compared with the primary tumors of metastasis-negative mice. These findings were confirmed in patients with cervical cancer. The v0 was higher in patients with pelvic lymph node metastases than those without lymph node involvement.

"These observations suggest that high IFP in tumors may promote lymph node metastasis and that Gd-DTPA-based DCE-MRI may provide valid information on the IFP of tumors," Hompland and colleagues conclude.


Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs